Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies
Open Access
- 1 January 2020
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 12
Abstract
Mesothelin is expressed at very low levels by normal mesothelial cells but is overexpressed in several human cancers. This makes mesothelin a promising target for immunotherapy. Limited data exist about mesothelin expression in esophageal carcinoma. In a current clinical trial, the highly potent anti-mesothelin antibody anetumab ravtansine is used in patients with mesothelin-positive tumors. Response rates are correlated with mesothelin expression (using the Ventana antibody) in tumor cells. No data are available on expression levels using the Ventana antibody. Most data have been generated using the Novocastra antibody. As patients are selected for clinical trials based on antibody staining of tumor samples, a comparison of these two available antibodies is crucial. We analyzed 481 esophageal carcinomas [373 esophageal adenocarcinomas (EACs), 108 esophageal squamous cell carcinomas (ESCCs)] using two different monoclonal antibodies (Novocastra and Ventana) for mesothelin expression (low–mid and high-level expression, as used in one clinical trial). We also checked for the correlation of these results with clinical and molecular data. We revealed different staining results for both antibodies in EACs: Ventana: 53.6% (low expression: 25.3%; high expression: 28.3%) and Novocastra: 35.7% (low expression: 21.2%; high expression 14.5%). In ESCC we found comparable staining results: Ventana: 13.3% (low expression: 9.5%; high expression: 3.8%) and Novocastra: 13% (low expression: 11.1%; high expression: 1.9%). ARID1a-deficient EAC patients demonstrated significantly higher rates of mesothelin-positive tumors than ARID1a intact EAC patients. No correlations were found with other molecular alterations (TP53 mutation, ERBB2 amplification) or survival rates. To the best of our knowledge, this is the largest study analyzing the importance of mesothelin expression in esophageal carcinoma. This study revealed a significant number of mesothelin-positive esophageal carcinomas, especially adenocarcinomas. New therapeutic targets are urgently required to improve the outcome of patients with locally advanced or metastasized esophageal carcinoma. The inhibition of mesothelin can be a new attractive target.Keywords
This publication has 29 references indexed in Scilit:
- Mesothelin, a novel immunotherapy target for triple negative breast cancerBreast Cancer Research and Treatment, 2012
- Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal AdenocarcinomaCancer Epidemiology, Biomarkers & Prevention, 2012
- High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaBritish Journal of Cancer, 2009
- A Binding Domain on Mesothelin for CA125/MUC16Journal of Biological Chemistry, 2009
- Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapyNanomedicine: Nanotechnology, Biology and Medicine, 2008
- Response Evaluation by Endoscopy, Rebiopsy, and Endoscopic Ultrasound Does Not Accurately Predict Histopathologic Regression After Neoadjuvant Chemoradiation for Esophageal CancerAnnals of Surgery, 2008
- Mesothelin Promotes Anchorage-Independent Growth and Prevents Anoikis via Extracellular Signal-Regulated Kinase Signaling Pathway in Human Breast Cancer CellsMolecular Cancer Research, 2008
- Laparoscopic Ischemic Conditioning of the Stomach for Esophageal ReplacementAnnals of Surgery, 2007
- Frequent expression of the tumor antigen cak1 in squamous‐cell carcinomasInternational Journal of Cancer, 1992
- Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesotheliumInternational Journal of Cancer, 1992